ADDF In The Media
The January episode of Innovations with Ed Begley, Jr. on Discovery Channel features the Alzheimer's Drug Discovery Foundation.
WMBC-TV talks to Dr. Howard Fillit about promising developments in Alzheimer's treatments at our 16th International Conference on Alzheimer's Drug Discovery.
This episode of "Faces of Philanthropy" focuses on mental wellness and features staff, supporters, and funded scientists from the ADDF.
Dr. Gary Gibson discusses his upcoming clinical trial with the Wall Street Journal's Tanya Rivero.
Of the 199 windows on the wavy walls of the Lou Ruvo Center for Brain Health in Las Vegas, no two are on the same plane. The setting uncannily echoed the vibe at Opportunities and Challenges in Combination Therapy for Alzheimer’s Disease, an advisory panel meeting that took place at the Frank Gehry-designed building on May 28.
Biogen Inc.'s recent revelation of promising early data from an experimental Alzheimer's treatment is something of a breakthrough: it's the first time that we have seen positive human data about a new Alzheimer's drug that can both reduce the presence of amyloid plaques in the brain and improve cognitive function.
A new study from the University of Texas Medical Branch at Galveston has revealed that a single dose of an immunotherapy reverses memory problems in an animal model of Alzheimer’s disease. Although it’s known that two molecules – tau and amyloid beta – are considered responsible for the disease’s progression, the relationship between these two proteins and resulting memory problems has remained unclear.
If the analysts are right, this Sunday Julianne Moore will win an Academy Award for her performance in "Still Alice." It's a powerful, important performance, bringing into focus a devastating disease that is all too often hidden from sight. But it's also an opportunity for Moore, who absorbed so many real stories in preparation for this all-consuming role, to do something more.
B. Smith, the well-known entertainment and lifestyle personality, had just come to my office for a consultation. In the year since her diagnosis of Alzheimer’s at a still-beautiful age 64, her family had clung to the words early stage, but after 90 minutes of geriatric assessment, it was clear to me that B.’s condition was considerably worse than anyone had thought.
The world's first clinical trials in London will explore whether the Viagra-style drug could help prevent a common form of dementia by increasing blood flow to the brain. Scientists will be using the drug Tadalafil, which works by dilating blood vessels, in helping to prevent the onset of vascular dementia, the second most common form of dementia which accounts for 110,000 cases in the UK.